A Phase I dose‐escalation study of DCLL9718S , an antibody‐drug conjugate targeting C ‐type lectin‐like molecule‐1 ( CLL ‐1) in patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

A Phase I dose‐escalation study of DCLL9718S , an antibody‐drug conjugate targeting C ‐type lectin‐like molecule‐1 ( CLL ‐1) in patients with acute myeloid leukemia

Published:2021-03-11 Issue:5 Volume:96 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Daver Naval¹^ORCID,Salhotra Amandeep²^ORCID,Brandwein Joseph M.³^ORCID,Podoltsev Nikolai A.⁴,Pollyea Daniel A.⁵,Jurcic Joseph G.⁶,Assouline Sarit⁷,Yee Karen⁸,Li Mengsong⁹,Pourmohamad Tony⁹,Samineni Divya⁹,Sumiyoshi Teiko⁹,Vaze Anjali⁹,Dere Randall C.⁹,Ma Connie⁹,Cooper James⁹

Affiliation:

1. Department of Leukemia MD Anderson Cancer Center Houston Texas

2. City of Hope Comprehensive Cancer Center Duarte California

3. University of Alberta Hospital Edmonton Alberta Canada

4. Yale University School of Medicine New Haven Connecticut

5. Division of Hematology, Department of Medicine University of Colorado Aurora Colorado

6. Columbia University Irving Medical Center New York Presbyterian Hospital, and Herbert Irving Comprehensive Cancer Center, Columbia University New York New York

7. Jewish General Hospital, McGill University Montreal Quebec Canada

8. Department of Medical Oncology Princess Margaret Hospital Toronto Ontario Canada

9. Genentech, Inc. South San Francisco California

Funder

Genentech

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26136

Reference9 articles.